Evaluating the Therapeutic Effect of Sofosbuvir in Outpatients with COVID-19: A Randomized Clinical Trial Study
Therapeutic Effect of Sofosbuvir on Outpatients with COVID-19
DOI:
https://doi.org/10.31661/gmj.v13i.3035Keywords:
Sofosbuvir, COVID-19, Mild Symptoms, MortalityAbstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has engendered scores of deaths worldwide. Just as the development of varying procedures during the pandemic has helped inhibit the disease, none is considered a definitive treatment protocol for this problem, as each induces some clinical complications pertinent to the disease. This study thus assessed the early use of sofosbuvir in outpatients with mild COVID-19. Materials and Methods: This randomized clinical trial study was conducted on 360 patients with mild COVID-19 infection at 17 Shahrivar Ahvaz Health Center. These patients were randomly divided into the intervention and control groups. Both the control and intervention groups received 400 mg of sofosbuvir and a placebo for seven days, respectively. After 14 days from the onset of the treatment, the duration of symptoms, the necessity of hospitalization, the mean of hospitalization duration, and mortality were assessed. Results: The most common symptoms in the intervention and control groups were coughs with a frequency of 46 (25.6%) and 54(30%), respectively. The two groups showed no statistically significant difference in the frequency of the first observed clinical symptom related to the disease (P=0.2). The mean days that the patients were symptomatic in the control group were 14±4.17, whereas, in the intervention group, it was 12.12±3.15 (P=0.08). The frequency of hospitalization in the control and intervention groups was 7 (3.8%) and 4 (2.22%), respectively (P=0.11). Moreover, the mean days of hospitalization in the control and the intervention groups were 4±1.1 and 3±0.8, respectively (P=0.15). In addition, the two groups had a similar frequency of hospitalization in the ICU (0) and mortality rate (0). Conclusion: Sofosbuvir alone cannot play a significant role in the treatment of outpatients with mild COVID-19.
References
Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946.
https://doi.org/10.1016/j.ijantimicag.2020.105946
PMid:32199877 PMCid:PMC7156123
Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-12.
https://doi.org/10.1016/j.jmii.2020.02.012
PMid:32173241 PMCid:PMC7128959
Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. Jama. 2020;324(13):1330-41.
https://doi.org/10.1001/jama.2020.17023
PMid:32876694 PMCid:PMC7489434
Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. Jama. 2021;326(6):499-518.
https://doi.org/10.1001/jama.2021.11330
PMid:34228774 PMCid:PMC8261689
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47.
https://doi.org/10.1038/nrd.2015.37
PMid:26868298 PMCid:PMC7097181
Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection, and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect. 2016; 22(10):826-32.
https://doi.org/10.1016/j.cmi.2016.08.025
PMid:27592089 PMCid:PMC5627509
Merat S. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clin Infect Dis. 2020;70 (10):2206-12.
https://doi.org/10.1093/cid/ciz628
PMid:31504303
Jockusch S, Tao C, Li X, Chien M, Kumar S, Morozova I, et al. Sofosbuvir-terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. SCi Rep. 2020;10(1):1-9.
https://doi.org/10.1038/s41598-020-73641-9
PMid:33024223 PMCid:PMC7538426
Bozorgmehr R, Amiri F, Hosein Zadeh M, Ghorbani F, Khameneh Bagheri A. Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial. Arch Acad Emerg Med. 2022; 10(1):e46-49.
Nourian A. Khalili H.Sofosbuvir as a potential option for the treatment of COVID-19. Acta Biomed. 2020; 91(2): 239-241.
Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3379-85.
https://doi.org/10.1093/jac/dkaa334
PMid:32812039 PMCid:PMC7454592
Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with the moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3373-8.
https://doi.org/10.1093/jac/dkaa332
PMid:32812025 PMCid:PMC7454669
Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020;75(11):3366-72.
https://doi.org/10.1093/jac/dkaa331
PMid:32812051 PMCid:PMC7529105
Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2021;76(3):753-7.
https://doi.org/10.1093/jac/dkaa501
PMid:33338232 PMCid:PMC7798988
Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, et al. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2021;76(8):2158-67.
https://doi.org/10.1093/jac/dkab152
PMid:34037760 PMCid:PMC8194643
Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021;76 (2):286-91.
https://doi.org/10.1093/jac/dkaa418
PMid:33063117 PMCid:PMC7665526
Zein A. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J. 2022; 98 (1161): 509-514.
https://doi.org/10.1136/postgradmedj-2021-140287
PMid:37066509
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
